Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,904 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: AstraZeneca Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

NCT05477108
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 28, 2026, 10:47 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

NCT07784725
View directory record Official record
Conditions
Obesity or Overweight
Interventions
AZD6234, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
33
States / cities
Dothan, Alabama • Huntsville, Alabama • Mesa, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 28, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma

NCT02814643
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Benralizumab Placebo, Seasonal influenza virus vaccine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 21 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Mesa, Arizona • Huntington Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 28, 2026, 10:47 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

NCT07013643
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO), Acetaminophen (APAP), AZD9550
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Glendale, California • Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 28, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.

NCT05587998
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Morphine, AZD4041, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 28, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

NCT06034743
View directory record Official record
Conditions
Uncontrolled Hypertension, Resistant Hypertension
Interventions
Baxdrostat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
796 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
43
States / cities
Saraland, Alabama • Scottsdale, Arizona • Sun City West, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 28, 2026, 10:47 AM EDT
Completed Not applicable Interventional Results available

Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244

NCT00970359
View directory record Official record
Conditions
Thyroid Cancer
Interventions
AZD6244
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 28, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer

NCT00687297
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer
Interventions
vandetanib induction, Docetaxel, Carboplatin, Placebo, Vandetanib maintenance
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
30
States / cities
Boca Raton, Florida • Lakeland, Florida • Rockford, Illinois + 26 more
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 28, 2026, 10:47 AM EDT
Completed Phase 2 Interventional Results available

Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease

NCT00296374
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Rosuvastatin, Atorvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
29
States / cities
Avondale, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2011 · Synced Oct 28, 2026, 10:47 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

NCT07000123
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
AZD0780, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
101
States / cities
Huntsville, Alabama • Irondale, Alabama • Mobile, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 28, 2026, 10:47 AM EDT
Recruiting Phase 2 Interventional

Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations

NCT03786796
View directory record Official record
Conditions
Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer, Renal Carcinoma, Kidney Cancer Metastatic
Interventions
Olaparib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 28, 2026, 10:47 AM EDT
Not listed Phase 2Phase 3 Interventional Results available

Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome

NCT02130882
View directory record Official record
Conditions
Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia
Interventions
benralizumab, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 28, 2026, 10:47 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial

NCT07490860
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Educational Intervention, Survey Administration, Interview, Electronic Health Record Review
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years to 77 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 28, 2026, 10:47 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Characterizing the Human Airway Immune Response to FluMist Vaccination

NCT07177417
View directory record Official record
Conditions
Healthy Young Adults, Influenza Vaccines, Influenza Vaccine Response
Interventions
FluMist, inactivated influenza vaccine, bronchoscopy
Biological · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 28, 2026, 10:47 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

NCT05048797
View directory record Official record
Conditions
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
Trastuzumab Deruxtecan, Cisplatin, Carboplatin, Pembrolizumab, Pemetrexed
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 123 Years
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Anchorage, Alaska • Los Alamitos, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 28, 2026, 10:47 AM EDT
Completed Phase 1 Interventional

Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

NCT00926731
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
AZD1152, LDAC (low dose cytosine arabinoside)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
60 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Cleveland, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2011 · Synced Oct 28, 2026, 10:47 AM EDT
Completed Phase 4 Interventional Results available

Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study

NCT02406677
View directory record Official record
Conditions
Cost Sharing, Acute Coronary Syndrome
Interventions
Study voucher card
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
11,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
271
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 224 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 28, 2026, 10:47 AM EDT
Completed Phase 4 Interventional Results available

To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation

NCT03060512
View directory record Official record
Conditions
Opioid Induced Constipation
Interventions
Polyethylene Glycol 3350, Movantik
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 84 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
53
States / cities
Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2018 · Synced Oct 28, 2026, 10:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..

NCT05955183
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5055, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 8, 2023 · Synced Oct 28, 2026, 10:47 AM EDT
Completed Phase 3 Interventional Results available

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT02296125
View directory record Official record
Conditions
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Interventions
AZD9291 80 mg/40 mg + placebo, Placebo Erlotinib 150/100mg, Placebo Gefitinib 250 mg, Erlotinib 150/100 mg, Gefitinib 250 mg, Placebo AZD9291 80 mg/ 40 mg
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
14
States / cities
Anaheim, California • Santa Rosa, California • West Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 28, 2026, 10:47 AM EDT
Recruiting Phase 2 Interventional

Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT03516617
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Acalabrutinib, Laboratory Biomarker Analysis, Obinutuzumab, Patient Observation, Quality-of-Life Assessment
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 10:47 AM EDT
Active, not recruiting Phase 2 Interventional

Phase IIa Study Evaluating AZD7798 in Crohn's Disease

NCT06450197
View directory record Official record
Conditions
Moderate to Severe Crohn's Disease
Interventions
AZD7798, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Escondido, California • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 10:47 AM EDT
Completed Phase 1 Interventional

AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies

NCT01065662
View directory record Official record
Conditions
Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
temsirolimus, cediranib
Drug
Lead sponsor
Susana M. Campos, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 28, 2026, 10:47 AM EDT
Completed Phase 4 Interventional Results available

Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)

NCT02973477
View directory record Official record
Conditions
Type2 Diabetes, Cardiovascular Diseases
Interventions
Dapagliflozin, Glimepiride
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 28, 2026, 10:47 AM EDT